

MONKEYPOX EXPLAINER
Monkeypox outbreak - an Imperial expert explains
The UK Health Security Agency is investigating four new cases of monkeypox in the UK. There are now a total of six confirmed cases.
Monkeypox outbreak - an Imperial expert explains
The UK Health Security Agency is investigating four new cases of monkeypox in the UK. There are now a total of six confirmed cases.
Low-cost, disease-detecting biosensors show global health promise
Researchers have developed low-cost, biodegradable biosensors for global health applications in resource-limited settings.
Inexpensive and rapid tests can distinguish between Chagas disease parasites
A new rapid diagnostic test that can differentiate between different strains of Chagas disease parasite could lead to a widespread testing programme.
1
ICB CDT student awarded BBSRC Flexible Talent Mobility Innovation Placement
ICB CDT student Mark Wilkinson has been awarded a BBSRC FTMA Innovation Placement and will spend 3 months attending the DDW unit at GSK, Madrid.
Imperial launches its first public health online degree
The Global Master of Public Health, developed alongside Coursera, is Imperial's first fully-online degree in the health field.
Experts reveal patterns of yellow fever risk, and warn against ignoring disease
Yellow fever kills around 80,000 people every year - and causes severe disease in a further 150,000.
1
Strengthening health systems to tackle schistosomiasis
SCI has been working with the Ministry of Health in Cote d'Ivoire to strengthen and develop its health systems to help combat schistosomiasis.
SCI recommended as a "Top Charity" for 7th consecutive year
GiveWell, an international charity evaluator, has recommended the SCI as a "Top Charity" once more for its impact and cost-effectiveness.
SCI awarded A+ rating by DFID for third year running
The SCI has received an excellent A+ rating from the UK government's
Department for International Development (DFID) for a third year running.
Funding received to complete paediatric schistosomiasis drug trial
European and Japanese funders have formed an exciting new partnership to complete the development of a paediatric schistosomiasis drug formulation.